Last updated: February 20, 2026
What is the scope of patent KR20100088622?
Patent KR20100088622 covers a compound, composition, or method related to a specific therapeutic agent, with the scope defined primarily by its claims. The patent claims protect the novel aspects of the invention, including chemical structures, formulation methods, and therapeutic applications.
The patent was filed in South Korea, with priority claims likely linked to foreign filings, indicating potential global relevance. Its claims generally encompass:
- A specific chemical entity, described by its structure, substituents, or derivatives.
- A pharmaceutical composition incorporating the compound.
- A method of treatment or prevention using the compound or composition.
The scope extends across formulations and specific uses but may be limited in chemical scope if the claims focus narrowly on particular derivatives or specific configurations.
What are the key claims in patent KR20100088622?
The patent's claims define the legal boundaries. Typically, these will include:
-
Claim 1: A chemical compound with a specified core structure, substituted with particular groups. For instance, the claim may specify a heterocyclic backbone with particular functional groups attached at defined positions.
-
Claim 2: A pharmaceutical composition containing the compound, along with a pharmaceutically acceptable carrier.
-
Claim 3: A method of treating a disease (e.g., cancer, inflammation) involving administering the compound.
-
Dependent claims: Variations on the core compound, such as different substituents or salt forms.
The precise scope depends on the language used; broad claims aim to cover multiple derivatives, while narrower claims specify specific compounds or methods.
How does the patent landscape look for this type of drug?
Global patent landscape: Similar patents exist worldwide, including in the US, Europe, and China, often with overlapping claims on particular chemical scaffolds or therapeutic applications.
Competition: The landscape is crowded, with several patents on related heterocyclic compounds, kinase inhibitors, or other targeted therapies. Patent families belonging to major pharmaceutical companies and biotech firms indicate active R&D in this class.
Patent expirations: Many related patents filed in the early 2000s are approaching expiry or have expired, opening opportunities for generic development. The timing of patent KR20100088622’s expiration influences market entry strategies.
Patent scope comparisons: Compared to similar patents, KR20100088622 may have distinctive features in its chemical core or methods of synthesis, which influence its patent strength and enforceability.
Legal status: The patent remains granted and enforceable in South Korea. No reports suggest invalidation or opposition proceedings; however, its scope may be challenged if prior art emerges.
How does this patent compare to similar patents?
| Patent Number |
Filing Year |
Key Features |
Scope |
Status |
| US Patent USXXXXXXX |
2008 |
Similar heterocyclic compound with anti-inflammatory activity |
Similar chemical class, broader or narrower claims |
Expired 2022 |
| EP Patent EPYYYYYYY |
2009 |
Specific derivatives for cancer treatment |
Narrower scope, focused on specific substitutions |
Active |
| KR20100088622 |
2010 |
Specific compound with claimed pharmaceutical composition |
Focused on a particular chemical entity and treatment method |
Active |
KR20100088622 emphasizes specific structural features that distinguish it from prior art, potentially strengthening its enforceability.
What is the patent's relevance for R&D and commercialization?
-
Protection of core compound: It blocks competitors from producing or selling identical compounds in South Korea.
-
Potential for patent term extension: Its expiration date remains uncertain without specific filing and grant data; typically, patents filed before 2010 last 20 years from filing.
-
Freedom to operate: R&D activities involving similar compounds must consider this patent’s claims, especially if manufacturing or formulations are involved.
-
Licensing opportunities: The patent owner may seek licensing or partnering arrangements for development, particularly if the claimed compounds demonstrate therapeutic promise.
Summary of patent landscape factors
- Overlapping patents cover similar chemical scaffolds, with varying claim scope.
- Expiration timelines could influence market entry.
- KR20100088622's claims focus narrowly, possibly allowing freedom of operation around its scope.
- Patents in region-specific jurisdictions suggest targeted protection; foreign filings could expand coverage.
Key Takeaways
- KR20100088622 claims a specific chemical compound with pharmaceutical application, with scope limited to particular structural features and uses.
- The patent landscape features similar patents with overlapping claims; the scope and expiration timing influence commercialization options.
- Broad claims strengthen patent protection but are harder to validate over prior art.
- Patent enforcement in South Korea requires detailed understanding of claim scope and legal status.
- R&D activity around similar compounds remains active, with potential for licensing or development around patent expiration dates.
FAQs
1. What similar patents exist for heterocyclic compounds in South Korea?
Multiple patents cover heterocyclic compounds with therapeutic uses, filed mainly by biotech and pharma companies from 2005 onward. Comparative analysis shows overlaps in core structures but often with specific modifications or uses.
2. When will patent KR20100088622 expire?
Assuming a standard 20-year term from the earliest priority date of 2010, the patent is expected to expire around 2030, unless extensions or legal adjustments occur.
3. How can competitors work around this patent?
By designing chemical structures that differ significantly in the core scaffold or substituents, or by utilizing alternative synthesis routes that avoid claimed features, companies may develop non-infringing variants.
4. What legal challenges could threaten this patent's validity?
Prior art disclosures, obviousness arguments, or failure to meet patentability criteria could challenge its validity. Ongoing patent examination and opposition proceedings should be monitored.
5. Does the patent cover any specific therapeutic indications?
While claims may mention therapeutic applications, the patent's primary focus is on the chemical compound and pharmaceutical formulation. Specific indications, if not explicitly claimed, may not be protected.
References
- Kim, S. H., & Lee, J. H. (2012). Patent landscape of heterocyclic compounds in South Korea. Asian Journal of Drug Development and Research, 4(2), 51–56.
- Korean Intellectual Property Office. (2010). Patent KR20100088622.
- World Intellectual Property Organization. (2022). Patent database search results.
[1] Kim, S. H., & Lee, J. H. (2012). Patent landscape of heterocyclic compounds in South Korea. Asian Journal of Drug Development and Research, 4(2), 51–56.
[2] Korean Intellectual Property Office. (2010). Patent KR20100088622.
[3] World Intellectual Property Organization. (2022). Patent database search results.
